{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:36:24Z","timestamp":1784752584394,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T00:00:00Z","timestamp":1425945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia patients display heterogeneous responses to imatinib. Survival depends on baseline clinical characteristics (including prognostic scoring systems) and on early response (such as &gt;10% BCR\u2010ABL\/ABL ratio at 3\u00a0months of therapy). The results of switching to second\u2010generation tyrosine kinase inhibitors (2<jats:styled-content style=\"fixed-case\">GTKI<\/jats:styled-content>s) may contain a bias since, in the majority of these studies, patients who switch treatment due to intolerance or failure are censored or excluded. We analyzed the <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>panish <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>egistry data on switching in an intention\u2010to\u2010treat analysis of patients in standard clinical practice. Switching to 2<jats:styled-content style=\"fixed-case\">GTKI<\/jats:styled-content>s improves responses from 45% to 75% of complete cytogenetic response (CCyR) and from 15% to 45% of major molecular response (MMR) in the group without molecular response 1 (MR1) at 3\u00a0months and from 70% to 87% in CCyR and from 52% to 87% in MMR in the group with MR1. The final response rate is poorer in the group with no MR1 at 3\u00a0months. Nevertheless, the differences in the rates of response were not translated into differences in major events (transformations or deaths), and the final progression\u2010free survival and overall survival were similar.<\/jats:p>","DOI":"10.1002\/cam4.440","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T10:48:47Z","timestamp":1425984527000},"page":"995-1002","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Switching to second\u2010generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib\u2010treated patients with chronic myeloid leukemia with more than 10% of BCR\u2010ABL\/ABL ratio at 3\u00a0months"],"prefix":"10.1002","volume":"4","author":[{"given":"Luis\u2010Felipe","family":"Casado","sequence":"first","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Virgen de la Salud Toledo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9\u2010Valent\u00edn","family":"Garc\u00eda\u2010Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitario Ram\u00f3n y Cajal Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Massagu\u00e9","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Valle de Hebr\u00f3n Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitario Miguel Servet Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"P\u00e9rez\u2010Encinas","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Cl\u00ednico Universitario de Santiago de Compostela Santiago de Compostela Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"de Paz","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitario La Paz Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez\u2010L\u00f3pez","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital 12 de Octubre Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiomar","family":"Bautista","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Puerta de Hierro Majadahonda Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Osorio","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital General Universitario Gregorio Mara\u00f1\u00f3n Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda\u2010Jos\u00e9","family":"Requena","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitario Severo Ochoa Legan\u00e9s Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Lozano Blesa Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda\u2010Jes\u00fas","family":"Pe\u00f1arrubia","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Cl\u00ednico Universitario de Valladolid Valladolid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Calle","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital General de Ciudad Real Ciudad Real Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9\u2010\u00c1ngel","family":"Hern\u00e1ndez\u2010Rivas","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitario Infanta Leonor Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Burgaleta","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitario Pr\u00edncipe de Asturias Alcal\u00e1 de Henares Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Maestro","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitario de la Princesa Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Garc\u00eda\u2010Orme\u00f1a","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Virgen de la Salud Toledo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan\u2010Luis","family":"Steegmann","sequence":"additional","affiliation":[{"name":"Registro Espa\u00f1ol de Investigaci\u00f3n y Tratamiento de Leucemia Mieloide Cr\u00f3nica (RELMC) [Spanish Registry for the Investigation and Treatment of Chronic Myeloid Leukemia] Madrid Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitario de la Princesa Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403686"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_7_4_1","first-page":"335","article-title":"The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha","volume":"90","author":"Hasford J.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-319038"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_7_9_1","first-page":"69","article-title":"Assessment of early molecular response as a predictor of long\u2010term clinical outcomes in the phase 3 BELA study","volume":"120","author":"Brummendorf T. H.","year":"2012","journal-title":"ASH Annual Meeting Abstracts."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-383711"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00117-6"},{"issue":"2","key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0125","article-title":"NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia","volume":"9","author":"O'Brien S.","year":"2011","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_7_17_1","first-page":"3771","article-title":"Early switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial","volume":"120","author":"Yeung D. T.","year":"2012","journal-title":"ASH Annual Meeting Abstracts."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090282"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.440","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T06:01:08Z","timestamp":1696572068000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,10]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/cam4.440"],"URL":"https:\/\/doi.org\/10.1002\/cam4.440","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,10]]},"assertion":[{"value":"2014-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}